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EdBACKGROUND Within the SCOT-HEART (Scottish COmputed Tomography of the HEART Trial) trial of patients with
stable chest pain, the use of coronary computed tomography angiography (CTA) reduced the rate of death from coronary
heart disease or nonfatal myocardial infarction (primary endpoint).
OBJECTIVES This study sought to assess the consistency and mechanisms of the 5-year reduction in this endpoint.
METHODS In this open-label trial, 4,146 participants were randomized to standard care alone or standard care plus
coronary CTA. This study explored the primary endpoint by symptoms, diagnosis, coronary revascularizations, and
preventative therapies.
RESULTS Event reductions were consistent across symptom and risk categories (p ¼ NS for interactions). In patients
who were not diagnosed with angina due to coronary heart disease, coronary CTA was associated with a lower primary
endpoint incidence rate (0.23; 95% conﬁdence interval [CI]: 0.13 to 0.35 vs. 0.59; 95% CI: 0.42 to 0.80 per 100 patient-
years; p < 0.001). In those who had undergone coronary CTA, rates of coronary revascularization were higher in the ﬁrst
year (hazard ratio [HR]: 1.21; 95% CI: 1.01 to 1.46; p ¼ 0.042) but lower beyond 1 year (HR: 0.59; 95% CI: 0.38 to 0.90;
p ¼ 0.015). Patients assigned to coronary CTA had higher rates of preventative therapies throughout follow-up
(p < 0.001 for all), with rates highest in those with CT-deﬁned coronary artery disease. Modeling studies demonstrated
the plausibility of the observed effect size.
CONCLUSIONS The beneﬁcial effect of coronary CTA on outcomes is consistent across subgroups with plausible
underlying mechanisms. Coronary CTA improves coronary heart disease outcomes by enabling better targeting
of preventative treatments to those with coronary artery disease. (Scottish COmputed Tomography of the
HEART Trial [SCOT-HEART]; NCT01149590) (J Am Coll Cardiol 2019;74:2058–70) © 2019 The Authors. Published by
Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/4.0/).N 0735-1097 https://doi.org/10.1016/j.jacc.2019.07.085
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2059AB BR E V I A T I O N S
AND ACRONYM S
CI = conﬁdence interval
CTA = computed tomography
angiography
HR = hazard ratio
NHS = National Health ServiceC oronary computed tomography angiography(CTA) has high sensitivity and speciﬁcity forthe detection of coronary artery disease
(1,2). This has prompted the evaluation of coronary
CTA as a diagnostic test for coronary artery disease
in patients presenting with stable chest pain. The
short-term beneﬁts of coronary CTA in this popula-
tion have included better diagnostic certainty, lower
rates of normal coronary arteries at the time of inva-
sive coronary angiography, and improved targeting
of symptomatic and preventative therapies (3,4).
Large-scale clinical trials have also suggested that
short-term coronary heart disease events are reduced
(4,5). In the SCOT-HEART (Scottish COmputed To-
mography of the HEART Trial), we recently reported
the effects of coronary CTA on the pre-speciﬁed 5-
year clinical outcomes including investigations, treat-
ments, and clinical events (6). We demonstrated that
an initial strategy of coronary CTA was associated
with a 41% relative risk reduction in coronary heart
disease death or nonfatal myocardial infarction at 5
years. This major reduction in events has prompted
questions about the mechanisms of beneﬁt, the po-
tential for bias, and the plausibility of the effect size.SEE PAGE 2071We here present further analyses of the 5-year data
from the SCOT-HEART trial to assess the robustness
of the event reductions seen with coronary CTA with
respect to the participant subgroups, the changes in
diagnosis, and the alterations to procedural and
pharmacological treatments. Drawing these disparate
effects together, we wanted to determine the overall
attribution of beneﬁts in relation to the primary
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Manuscript received April 16, 2019; revised manuscript received July 23, 20METHODS
The study population and trial design were
reported previously (4,5,7). In brief, adult
patients age #75 years who attended the
outpatient cardiology clinic with stable chest
pain were invited to participate in the trial in
12 cardiology centers across Scotland between
2010 and 2014. They were randomized 1:1 to standard
care alone or standard care plus coronary CTA.
Attending clinician-directed changes in diagnosis,
investigations, and treatments were documented at
6 weeks, and changes in investigations, treatments,
and clinical outcomes over 5 years were obtained from
nationwide routinely collected health care data
through National Health Service (NHS) Scotland.
SYMPTOMS. Participants without a prior history of
coronary heart disease comprised 91% of the study
population and were categorized into those with
nonanginal chest pain and a normal 12-lead electro-
cardiogram (nonanginal chest pain), and those with
either typical or atypical chest pain, or nonanginal
chest pain and an abnormal electrocardiogram
(possible angina) as per the National Institute for
Health and Care Excellence guidelines (7,8).
10-YEAR CARDIOVASCULAR RISK. The 10-year car-
diovascular risk of participants was determined by
the ASSIGN score. This score is based on traditional
cardiovascular risk factors but also incorporates other
risk markers including social deprivation and family
history of cardiovascular disease and has been
calibrated for the Scottish population (9). To avoid
potential for bias, changes in diagnosis, in-
vestigations, and treatments were documented
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TABLE 1 Baseline Characteristics of Trial Participants
All Participants
(N ¼ 4,146, 100%)
Standard Care þ Coronary CTA
(n ¼ 2,073, 50%)
Standard Care
(n ¼ 2,073, 50%)
Male 2,325 (56) 1,162 (56) 1,163 (56)
Age, yrs 57  10 57  10 57  10
Chest pain group
Nonanginal chest pain 1,447 (35) 712 (34) 735 (35)
Possible angina 2,323 (56) 1,174 (57) 1,149 (56)
Prior CHD 372 (9) 186 (9) 186 (9)
Risk factors
Smoking habit 2,185 (53) 1,095 (53) 1,090 (53)
Hypertension 1,395 (34) 712 (34) 683 (33)
Diabetes mellitus 444 (11) 223 (11) 221 (11)
Hypercholesterolemia 2,176 (53) 1,099 (53) 1,077 (52)
Family history of CHD 1,716 (41) 887 (43) 829 (40)
Baseline therapy
Antiplatelet agent 1,993 (48) 1,009 (49) 984 (48)
Statin 1,786 (43) 902 (44) 884 (43)
Predicted 10-yr CHD risk,
%
17  12 18  11 17  12
Values are n (%) or mean  SD.
CHD ¼ coronary heart disease; CTA ¼ computed tomography angiography.
TABLE 2
Deﬁned b
Diagnostic
Nonangina
Possible a
Prior CHD
Values are n
NICE ¼ N
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ASSIGN score (standard care alone) (10).
CORONARY REVASCULARIZATION. Coronary revas-
cularization procedures (percutaneous coronary
intervention and coronary artery bypass graft sur-
gery) were identiﬁed from inpatient and day-case
episodes, and coronary disease burden was quanti-
ﬁed using centralized review of individual coronary
angiograms blinded to allocated intervention (3,4,6).
PREVENTATIVE THERAPIES. The Scottish national
community drug-prescribing database of the Infor-
mation and Statistics Division in NHS Scotland
maintains a detailed record of all NHS prescriptions
dispensed in the community, which are linked to in-
dividual patient identiﬁers (3,4,6). All prescriptions
are dispensed by community pharmacies, dispensing
doctors, and a small number of specialist suppliers.
CLINICAL FOLLOW-UP. Clinical data and deaths
were obtained from the Information and Statistics
Division and the electronic Data Research andCoronary CTA Findings According to Diagnostic Classiﬁcation as
y the NICE Guideline for the Assessment of Chest Pain
Coronary CTA Result
classiﬁcation Normal Nonobstructive Obstructive
l (n ¼ 591) 296 (50.1) 239 (40.4) 56 (9.5)
ngina (n ¼ 1,028) 340 (33.1) 385 (37.5) 303 (29.5)
(n ¼ 162) 13 (8.0) 56 (34.6) 93 (57.4)
(%) and include only those with a diagnostic coronary CTA result available.
ational Institute of Health and Care Excellence; other abbreviations as in Table 1.Innovation Service of NHS Scotland up to March 31,
2018. To account for reporting delays in data
completeness (6 to 8 weeks), outcomes were deter-
mined up to January 31, 2018. Previous analyses have
demonstrated an excellent correlation (>95%) be-
tween clinical events identiﬁed through Scottish
health record linkage and clinical events recorded
and adjudicated as part of a regulated clinical trial
(11). This has been successfully applied in other set-
tings (12,13) and for longer-term clinical trial follow-
up (14).
STATISTICAL ANALYSIS. This was a post hoc anal-
ysis of the SCOT-HEART trial. Clinical outcomes were
analyzed using Cox regression, adjusted for center
and minimization variables, with cumulative event
curves constructed. We performed a landmark anal-
ysis at 12 months, reasoning that coronary CTA–
driven alterations in invasive coronary angiography
and coronary revascularization should have been
completed by this time point. Data are presented as
mean  SD, median (interquartile range), and hazard
ratio (HR) or odds ratio (95% conﬁdence interval [CI])
as appropriate. No correction for multiplicity was
undertaken when testing secondary or
other outcomes.
As the SCOT-HEART trial randomized the applica-
tion of coronary CTA as a diagnostic intervention, it
cannot deﬁnitively determine the mediation pathway
for the treatment effects demonstrated. To explore
the plausibility of the treatment effect, we performed
a modeling study aiming to estimate the mean
outcome for patients in the coronary CTA group
under a counterfactual scenario wherein the man-
agement of patients in the coronary CTA group was
the same as that observed in the standard care group.
The full set of assumptions are given in the Online
Appendix. However, we wish to highlight that we
modeled a scenario wherein the highest risk (most
appropriate) patients were those who had received
additional preventative therapies as a result of the
coronary CTA intervention given that this would be
the consequence of improved diagnostic precision.
Under the observed difference between the trial arms
in use of preventative therapies, this represents a
best-case scenario.
Statistical signiﬁcance was taken as a 2-sided
p < 0.05. All analysis was undertaken using
R version 3.5.0 (R Foundation, Vienna, Austria).
RESULTS
We randomized 4,146 patients with stable chest pain
at 12 cardiology centers across Scotland to either
standard of care alone (n ¼ 2,073) or standard of care
FIGURE 1 Cumulative Incidence of CHD Death or Nonfatal MI
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Cumulative incidence curves for coronary heart disease (CHD) death or nonfatal myocardial infarction (MI) in (A) patients with nonanginal chest pain, (B) patients with
possible angina, and (C) patients with prior CHD, allocated to standard care alone (red) and computed tomography coronary angiography (CTCA) plus standard of care
(blue). (D) Instantaneous hazards over time for each of the 3 chest pain groups. Patients in the nonanginal group (blue) have a low risk of the primary endpoint that is
constant over time. Patients in the prior CHD group (gray) are at highest risk but the magnitude of risk is greatest during the ﬁrst 1 to 2 years. Patients in the possible
angina group (red) have a high early risk that rapidly declines over the ﬁrst 6 to 12 months.
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2061plus coronary CTA (n ¼ 2,073). Participants were
middle aged, had a high prevalence of cardiovascular
risk factors, and had a slight male preponderance
(Table 1).
SYMPTOMS AND PRIOR CORONARY HEART DISEASE. Of
the 4,146 study participants, there were 1,447 pa-
tients with nonanginal chest pain and a normal
resting electrocardiogram, 2,323 with possible angina,
and 372 with prior coronary heart disease. Four pa-
tients were excluded due to incomplete symptom
descriptions. Nonobstructive or obstructive diseasewas identiﬁed on coronary CTA in 49.9% of those
with nonanginal chest pain and 66.9% of those with
possible angina (Table 2). All 3 groups derived similar
relative beneﬁt from coronary CTA (p value for
interaction $0.50), although the absolute magnitude
and temporal pattern of beneﬁt appeared to vary
(Figure 1). Among patients with nonanginal chest
pain, the event rate appeared relatively constant over
time with the beneﬁts of coronary CTA only apparent
over a more prolonged time period (>1 year). In
contrast, patients with prior coronary heart disease
were at higher risk of events, especially in the early
FIGURE 2 5-Year Incidence Rates of CHD Death or Nonfatal MI
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Five-year incidence rates of CHD death or nonfatal MI in patients with (right) and without (left) a diagnosis of angina due to CHD 6 weeks after
randomization according to the trial allocation of standard care alone (red) and computed tomography coronary angiography plus standard of care (blue).
Abbreviations as in Figure 1.
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2062follow-up period, and the beneﬁts of coronary CTA
were more immediately apparent. Compared with
these groups, patients with possible angina were at
intermediate risk and demonstrated an intermediate
time course of beneﬁt.
DIAGNOSIS. We have previously reported that the
diagnosis of angina due to coronary heart disease was
changed in 1 in 4 patients following coronary CTA (4).
Among patients where the diagnosis of angina due to
coronary heart disease was not made, those in the
coronary CTA group had a lower incidence rate of
coronary heart disease death or nonfatal myocardial
infarction compared with the standard care group
(incidence rate: 0.23; 95% CI: 0.13 to 0.35 vs. 0.59;
95% CI: 0.42 to 0.80 per 100 patient-years, respec-
tively; p < 0.001) (Figure 2). The ﬁndings on coronary
CTA were strongly predictive of future risk of coro-
nary heart disease death or nonfatal myocardial
infarction (Online Figure 1).
CORONARY ANGIOGRAPHY AND REVASCULARIZATION.
Among patients referred for invasive coronary
angiography, those randomized to CTA had moreextensive burden of coronary artery disease
(p ¼ 0.056) (Table 3). This ﬁnding was particularly
notable among participants without inducible
ischemia on exercise testing (Online Table 1). At the
end of 1 year, more patients who had undergone
coronary CTA received coronary revascularization
(246 vs. 208; HR: 1.21; 95% CI: 1.01 to 1.46; p ¼ 0.042)
(Figure 3). Coronary revascularization was predomi-
nantly percutaneous coronary intervention (n ¼ 353;
8.5%) although one-quarter of patients (n ¼ 111; 2.7%)
underwent coronary artery bypass graft surgery.
Beyond 1 year, 33 coronary revascularizations
occurred in the coronary CTA group compared with 59
in the standard care group (HR: 0.59; 95% CI: 0.38 to
0.90; p ¼ 0.015). Of these, 8 coronary re-
vascularizations were prompted by myocardial
infarction in the coronary CTA group, and 18 in the
standard care group (HR: 0.45; 95% CI: 0.20 to
1.04; p ¼ 0.061).
PREVENTATIVE THERAPIES. Within the coronary
CTA group, 99% of participants with evidence of
inducible ischemia on exercise testing were already
TABLE 3 Findings on Invasive Coronary Angiography Performed Within
1 Year of Randomization
Standard Care Coronary CTA p Value
Number of coronary arteries
with $50% stenosis
0.014*
0 157 (39.3) 120 (28.6)
1 109 (27.3) 135 (32.3)
2 73 (18.3) 93 (22.2)
3þ 60 (15.0) 71 (16.9)
Number of coronary arteries
with $70% stenosis†
0.059*
0 176 (44.1) 152 (36.3)
1 125 (31.3) 144 (34.4)
2 54 (13.5) 74 (17.7)
3þ 44 (11.0) 49 (11.7)
Prognostically important CAD‡ 76 (19.0) 94 (22.4) 0.268§
Values are n (%). *These p values were determined from Cochran-Armitage test for trend. †Also
includes $50% stenosis of left main coronary artery. ‡Prognostically important CAD deﬁned as
any of the following: $50% stenosis of left main coronary artery; $70% stenosis of at least 3
main epicardial arteries; or $70% stenosis of at least 2 epicardial arteries including the proximal
left anterior descending artery. §This p value was determined using Pearson chi-square test.
CAD ¼ coronary artery disease; CTA ¼ computed tomography angiography.
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2063receiving preventative medications at the baseline
visit. In contrast, only 50% of participants were
receiving preventative treatments in those who had a
normal exercise test and evidence of nonobstructive
or obstructive coronary artery disease on coronary
CTA (Online Table 2). Following clinic consultation, 1
in 20 patients (5%) had their treatment altered at
6 weeks in the standard care arm compared with
nearly 1 in 4 (23%) in the coronary CTA group (Table 4)
(4). In particular, there were differences in the pre-
scription of both antiplatelet and statin therapies that
were sustained over the 5 years of follow-up
(Figure 4). Of note, antiplatelet therapy use fell from
48% (baseline) to 41% (at 1 year) in the standard of
care arm (p < 0.001), whereas it increased from 49%
(baseline) to 52% (at 1 year) in those assigned to cor-
onary CTA (p ¼ 0.017). In contrast, overall statin use
increased in both groups (standard care: 43% to 50%;
coronary CTA: 44% to 59%; p < 0.001 for both groups)
but this was greater in those assigned to coronary CTA
(p < 0.001). Compared with those without coronary
heart disease, rates of antiplatelet and statin thera-
pies were markedly higher in patients who had cor-
onary heart disease documented on the coronary CTA
despite comparable 10-year cardiovascular risk scores
(Figure 5). This was most apparent in participants
with lower cardiovascular risk scores.
MODELING TREATMENT EFFECTS. For the baseline
model, there were 48.5 and 82.4 estimated events in
the coronary CTA and standard care groups, respec-
tively. This was similar to the observed number of
events in each group (48 and 81 events, respectively).
Under the counterfactual scenario where the propor-
tion of participants receiving preventative therapy
was the same in both arms, the estimated number of
events in the coronary CTA group was 84.4 (i.e.,
similar to that observed in the control arm).DISCUSSION
We report a post hoc analysis of the long-term follow-
up of the SCOT-HEART trial participants in response
to questions raised about the consistency and plau-
sibility of the reported effect size. We demonstrate a
consistency of effect on event rates across the
differing trial subpopulations in keeping with their
presentation and risk proﬁle. We further demonstrate
that greater diagnostic certainty led to better cate-
gorization and risk stratiﬁcation with increased use of
procedural and pharmacological interventions in the
coronary CTA group. As a result of this improved
diagnostic performance and risk classiﬁcation, we can
plausibly account for much of the observed effect sizeby the targeted application of these preventative
interventions.
The SCOT-HEART trial included a broad range of
patients who were at low, intermediate, and high risk
of coronary events, as well as patients with prior
coronary heart disease (7,15). In the current analysis,
we categorized patients according to the National
Institute of Health and Care Excellence classiﬁcation
into those with nonanginal chest pain, possible
angina, and known coronary heart disease
(Central Illustration). Those participants with non-
anginal chest pain had the lowest event rates, and
these were linear over time. Moreover, the apparent
beneﬁts of coronary CTA were slow to accrue with a
continuous rate of separation in events with time that
appeared to take >1 year to be realized. These fea-
tures are consistent with the event rates and time
course of effects seen in primary prevention trials
(16). In contrast, participants with possible angina
had a higher and time-varying event rate with
increased early hazards consistent with some in-
dividuals having higher risk disease, namely new
onset angina (4,17,18). Patients with known coronary
heart disease were already on established preventa-
tive therapies and the beneﬁt appears to be rapid and
early, consistent with an effect of coronary
revascularization.
One of the main advantages of coronary CTA is its
negative predictive value. As such, it moves beyond
traditional symptom assessment and ischemia
testing, providing conﬁdence to clinicians and pa-
tients alike regarding the absence of disease. This was
TABLE 4 Prescribed
Coro
Normal (n ¼ 649)
Nonobstructive (n ¼ 6
Obstructive (n ¼ 452)
Prognostically importa
Values are n (%). *Denomin
least 3 main epicardial arte
Abbreviations as in Tabl
FIGURE 3 Cumulative Incidence of Coronary Revascularization Within the First Year and Beyond 1 Year
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Landmark analysis demonstration cumulative incidence curves for coronary revascularization within the ﬁrst year and beyond 1 year in patients allocated to
standard care alone (red) and computed tomography coronary angiography (CTCA) plus standard of care (blue).
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2064reﬂected in the increased number of patients in
whom a diagnosis of angina was excluded and pre-
ventive therapies discontinued in the coronary CTA
group (3,4). We observed that the event rate among
this group was much lower than the equivalent
diagnostic classiﬁcation in the standard care group,
which is consistent with the high negative predictive
value and diagnostic accuracy of coronary CTA and
implies greater diagnostic misclassiﬁcation of pa-
tients in the standard care arm contributed to their
higher event rate. False negative misclassiﬁcation isTherapy and Coronary Revascularization According to Coronary CTA Find
nary CTA Result
Antiplatelet Therapy
Baseline New*
227 (35.0) 1 (0.2)
80) 334 (49.1) 148 (42.8)
343 (75.9) 62 (56.9)
nt CAD on coronary CTA (n ¼ 178)† 148 (83.1) 16 (53.3)
ator excludes those receiving therapy at baseline. †Prognostically important CAD deﬁned as a
ries; or $70% stenosis of at least 2 epicardial arteries including the proximal left anterior
es 1 and 3.common and previous reports (19) have highlighted
that up to one-third of myocardial infarctions occur
in patients who had previously been diagnosed with
noncardiac chest pain. This ﬁnding was reproduced
in the standard care group of the SCOT-HEART trial.
Moreover, our modeling suggests that the use of
coronary CTA can, via increased identiﬁcation and
treatment of previously unrecognized predominantly
nonobstructive coronary heart disease, plausibly
reduce event rates among those with nonanginal
chest pain.ings
Statin Therapy Coronary Revascularization
Baseline New* During First Year
158 (24.3) 2 (0.4) 0 (0.0)
326 (47.9) 160 (45.2) 27 (4.0)
327 (72.3) 56 (44.8) 197 (43.6)
142 (79.8) 14 (38.9) 98 (55.1)
ny of the following:$50% stenosis of left main coronary artery;$70% stenosis of at
descending artery.
FIGURE 4 Prescribing of Preventative Therapy Over 5 Years of Follow-Up
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Frequency of prescribing for (A) antiplatelet and (B) statin therapy across 5 years in patients allocated to standard care alone (red) and computed
tomography coronary angiography plus standard of care (blue). The error bars relate to conﬁdence intervals for comparison between trial arms. p < 0.001
for all comparisons except baseline where p ¼ NS.
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FIGURE 5 Interaction Between Coronary CT Angiography Findings and Clinically Estimated Cardiovascular Risk in Relation to
Prescribing of Preventative Therapy
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Findings on Coronary CT Angiography
Normal Non-Obstructive Obstructive
Frequency of prescribing for (A) antiplatelet and (B) statin therapy at 6 weeks in patients with obstructive (orange) and nonobstructive
(purple) coronary artery disease, and normal coronary arteries (gray) on coronary computed tomography (CT) angiography across a range of
10-year cardiovascular risk as determined from the ASSIGN score (11). The lines and corresponding shaded areas represent the prescribing
estimates and 95% conﬁdence intervals derived from a regression model. The dots represent the observed prescribing rates among the trial
cohort grouped according to ASSIGN score with size proportional to the number of patients included in each group.
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2066Coronary CTA is the only widely available and well
validated noninvasive diagnostic technique able to
identify nonobstructive coronary plaque disease.
Standard approaches focusing on noninvasive
ischemia testing have relatively poor sensitivity forobstructive coronary disease and, by deﬁnition, are
unable to differentiate patients with normal coronary
arteries from those with nonobstructive plaque dis-
ease. Furthermore, we have shown for the ﬁrst time
that the identiﬁcation of nonobstructive coronary
CENTRAL ILLUSTRATION Coronary Computed Tomography Angiography Findings and Timing of Clinical Events
According to Chest Pain Symptoms
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Adamson, P.D. et al. J Am Coll Cardiol. 2019;74(16):2058–70.
Findings on coronary computed tomography angiography (left), changes in provision of preventative medications and early coronary revascularization (center), and
timing of coronary heart disease death or nonfatal myocardial infarction events (right) according to the National Institute of Health and Care Excellence guideline
classiﬁcation of chest pain symptoms.
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2067disease was a key factor associated with de novo
provision of evidence-based preventative therapies
among those who underwent coronary CTA.
Coronary revascularization was more common in
the coronary CTA group during the ﬁrst year after
randomization. We here show this reﬂects increased
early detection of obstructive coronary artery disease
that includes left main stem and triple vessel disease.
Coronary revascularization may be particularly im-
pactful in those with prognostic disease and those
with new onset, rapidly progressing, or recurrentangina, in whom underlying atherosclerotic disease
process may be more active. This is potentially
important as coronary revascularization is known to
reduce ischemic coronary events and improve clinical
outcomes in these more unstable clinical contexts
(20,21). In contrast, beyond 1 year, rates of coronary
revascularization were higher in those who had
received standard care alone and many of these
revascularization episodes were triggered by
myocardial infarction. This suggests that standard
care may be associated with missed diagnoses of
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2068coronary artery disease that later declare themselves,
whereas coronary CTA correctly identiﬁes those who
require treatment and thereby reduces future events.
There were important differences in the changes to
pharmacological therapies seen within the 2 trial
groups. First, antiplatelet therapy use fell in the
standard care group but rose in the coronary CTA
group, whereas statin use increased in both groups
albeit there were greater increases in the coronary
CTA group. Antiplatelet therapy at baseline in part
reﬂects diagnostic uncertainty on the part of the pri-
mary care physician who may have initiated preven-
tative therapy while awaiting specialist review. The
high diagnostic sensitivity of coronary CTA resulted
in an increased diagnosis of coronary artery disease
(especially nonobstructive disease) and consequently
increased prescribing of antiplatelet therapy in this
group. In contrast, the reduced ability to detect
nonobstructive coronary disease in the standard care
group resulted in treatment discontinuation in many
participants. Although the overall differences in pre-
scribing may appear modest, it should not be
forgotten, it is the distribution of such therapies that
is important and many patients in the standard care
group may be receiving futile treatments because
many will not have underlying coronary disease. For
the ﬁrst time, we here report that those undergoing
coronary CTA will have more directed and appro-
priate therapies. Indeed, when we look at those who
underwent coronary CTA, the rates of antiplatelet and
statin therapy use were almost 3-fold higher in those
with coronary artery disease compared with those
without disease despite identical 10-year cardiovas-
cular risk scores. Thus, simply looking at the overall
frequency of prescribing of preventative therapies
ignores the importance of how such medications are
distributed within a population. Again, these ﬁndings
suggest that coronary CTA is consistent with a preci-
sion medicine approach by identifying the most
appropriate treatment for each patient.
Using treatment effect estimates from published
randomized controlled trials, systematic reviews, and
meta-analyses (14,16,21–26), we explored for the ﬁrst
time whether the effect of additional treatment with
antiplatelet, statin, and revascularization in-
terventions could account for the observed effect
size. Whereas this modeling required a number of
assumptions, they were nonetheless reasonable, and
more reasonable than assuming that patients
receiving additional treatment in the coronary CTA
group shared the same cardiovascular event rate as
the entire cohort. This modeling allowed us to
demonstrate that at least some of the effect size we
observed was plausible and could be accounted for bycurrent evidence. In addition, we would also high-
light that the effect size reported in the SCOT-HEART
trial is consistent with rates of myocardial infarction
reported in other trials of coronary CTA in patients
with stable chest pain (5,27) and meta-analyses
(28,29), as well as large-scale observation studies
(30). Moreover, our model neither accounts for posi-
tive lifestyle changes, such as smoking cessation, nor
treatment compliance, which may also have a bene-
ﬁcial impact given the greater uptake of antiplatelet
and statin therapy in those diagnosed with coronary
artery disease by coronary CTA. We accept that many
of our modeling choices are necessarily subjective,
and we are pleased to provide access to the data to
allow other researchers to test the effect of different
assumptions. Finally, we would highlight that the
magnitude of the effect size we described in the
SCOT-HEART trial is consistent with other diagnostic
studies in patients with suspected coronary heart
disease (14), as well as primary prevention trials in
patients with interventions targeted to those at
higher risk, such as the JUPITER (Justiﬁcation for the
Use of Statins in Primary Prevention: An Intervention
Trial Evaluating Rosuvastatin) trial (20).
The identiﬁcation of disease is inextricably linked
to downstream changes in lifestyle, initiation and
intensiﬁcation of preventative therapies, and the
judicious use of coronary revascularization. The
combined effect of all of these interventions on cor-
onary atherosclerosis reduces the future risk of
myocardial infarction. In this regard, it was intriguing
to observe that the beneﬁts of coronary CTA were
similar regardless of presentation symptoms and
indeed the greatest proportionate beneﬁt was seen in
patients without a diagnosis of angina due to coro-
nary heart disease. This begs the question of whether
coronary CTA has a role in primary prevention of
coronary heart disease, and this will be the subject of
the forthcoming SCOT-HEART 2 trial.
STUDY LIMITATIONS. Some have highlighted that
there may have been bias in the reporting of out-
comes in the SCOT-HEART trial: something that
should always be considered in an open-label trial.
However, we think this is unlikely. First, the delayed
separation of the event curves suggests that there was
no early bias in event reporting because the CT result
would be available after 2 weeks, whereas treatment
changes took a further 4 to 6 weeks to implement.
Second, the ﬁnding that coronary CTA was associated
with less normal invasive coronary angiography and
higher early rates of revascularization suggests that
the coronary CTA more accurately identiﬁed the dis-
ease process. Third, coronary CTA increased the rate
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: Adding coronary CTA to standard care in patients with
stable chest pain syndromes can reduce myocardial infarction
and death over 5 years by facilitating evidenced therapy for
those with coronary artery disease independent of symptom
characteristics.
TRANSLATIONAL OUTLOOK: Future studies should evaluate
the value of coronary CTA to guide treatment of asymptomatic
patients at risk of coronary events.
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2069of diagnosis of coronary artery disease and intuitively
would be more inclined to increase the diagnosis of
myocardial infarction, which would act against any
potential beneﬁts of the trial intervention. Fourth,
the early increase followed by later reductions in
coronary revascularization in the coronary CTA group
does not support the postulation of ascertainment
bias. Why would these rates suddenly change direc-
tion? Fifth, the patterns of event reduction are
consistent across the trial subpopulations with both
lower risk nonanginal chest pain and higher risk new
onset angina pectoris responding to changes in
treatment as previously reported in primary and
secondary prevention trials. Sixth, although we did
not undertake clinical endpoint adjudication, we do
not believe that this is likely to have affected our
ﬁndings. A large analysis involving 10 cardiovascular
trials has demonstrated the process of blinded
endpoint adjudication changes neither the number of
endpoint events identiﬁed nor the overall treatment
effect estimate for the randomized intervention (31).
A recent Cochrane Systematic Review (32) has also
reported similar trial outcomes irrespective of central
versus local endpoint determination. Ultimately, for a
pragmatic trial determining the effect of introducing
a new diagnostic test into a health care system, the
main goal is to establish the impact on health care
outcomes as reported by that health care system. We
believe clinical outcomes reported by routine health
records data remain the most appropriate, indepen-
dent, and accurate method of clinical endpoint
ascertainment for the SCOT-HEART trial. Finally, we
acknowledge our modeling approach does assume
that the highest risk patients were those who had
received additional preventative therapies as a result
of the coronary CTA intervention, and this may have
overestimated some of the beneﬁts. This is particu-
larly applicable to the assumption of treatment
beneﬁt derived from coronary revascularization.Although we chose treatment effects applicable to
an unstable angina population, we believe this is
justiﬁable as the shape of the instantaneous hazard
curves supports a high short-term risk that plateaus
after 6 to 12 months in a pattern consistent with acute
coronary syndrome populations.
CONCLUSIONS
We have presented a multifaceted analysis that
consistently and robustly demonstrates the plausi-
bility of a reduction in long-term coronary events
consequent on investigating patients with stable
chest pain using coronary CTA. If we are to improve
the prevention of future myocardial infarction, coro-
nary CTA would appear to be the most effective and
indeed the only proven investigative approach in
patients with stable chest pain.
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APPENDIX For supplemental methods,
a ﬁgure, and tables, please see the online
version of this paper.
